145 results about "Renal tissue" patented technology

Biocompatible tissue repair implant devices and their methods of use are provided for repairing a diseased kidney tissue. The present invention relates to methods of removing a portion of kidney tissue from a host or donor, mincing it, placing it on a bioresorbable scaffold, and implanting the scaffold into a defect site in a kidney of a host or patient for use in the treatment of degenerative kidney diseases. The compositions and methods provide a pluripotent milieu for the de-novo generation of renal tubular structures in the replacement of diseased kidney tissue. The processes and devices are useful in the treatment of medical conditions and diseases relating to the kidneys such as trauma, necrosis, and both acute and chronic forms of renal failure.

A system for use in a renal denervation procedure includes a catheter having proximal and distal end portions, a sensor configured to sense a condition of one or more nerves, the sensor operatively associated with the distal end portion of the catheter, and at least one electrode disposed on the distal end portion of the catheter for delivering energy to renal tissue. A catheter includes a catheter body defining a distal end portion and a proximal end portion, and a sensor for sensing a renal sympathetic nerve, the sensor disposed on the distal end portion of the catheter body, wherein the sensor is configured to sense an electromagnetic signal from the renal sympathetic nerve.

Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising: providing renal tissue; mixing the renal tissue with a solution comprising a polymer, thereby forming a tissue-polymer suspension; extruding the tissue-polymer suspension into an bead-forming solution, thereby forming a therapeutic implant comprising beads of said polymer within which the renal tissue is encapsulated.

The present invention relates to a method for identifying neovascular structures in mammalian tissue, wherein said neovascular structures are identified by the detection of at least one specific protein in said tissue. It also relates to a method for identifying diseases or conditions associated with neovascularization, methods for targeting and / or imaging neovascular structures and methods for targeting diseases or conditions associated with neovascularization. Furthermore, the present invention is directed to the use of novel and / or known ligands, preferably antibodies, directed against novel and / or known target proteins for identifying tumor cells in mammalian tissue, preferably mammalian kidney tissue, more preferably mammalian vascular kidney tissue. The present invention also relates to novel ligands, preferably antibodies, fusion proteins comprising said ligands or antibodies, pharmaceutical and diagnostic compositions comprising said ligands, antibodies or fusion proteins, diagnostic and therapeutic methods as well as novel proteins and corresponding polynucleotides, vectors and host cells.

A method for distant hybridization between subfamilies of cyprinus carpio and megalobrama amblycephala includes the following steps that firstly, female cyprinus carpio and male megalobrama amblycephala which have obvious sexual maturity characteristics and good somatic features are selected as parent fishes for special pool breeding, then, artificial spawning induction is conducted on the parent finishes in a breeding season, the parent fishes with a good spawning induction effect are selected to be subjected to artificial dry-method fertilization, running water incubation is conducted on fertilized embryos in a pure water incubation device, fish fry are raised after being incubated, the raised fish fry are detected and screened, hybrid offspring of the cyprinus carpio and the megalobrama amblycephala are obtained through flow cytometry DNA content determination and renal tissue chromosome ploidy detection, and the hybrid offspring comprise diploid natural gynogenesis cyprinus carpio, diploid natural gynogenesis mirror carps, diploid fish like the cyprinus carpio and tetraploid hybrid fish. The method has the advantages that the rate of fertilization is high, the incubating rate is high, the offspring are excellent in character, and the method has great significance in genetic breeding.

The invention discloses a traditional Chinese medicine composition for improving renal functions and restraining renal fibrosis. Active pharmaceutical ingredients of the traditional Chinese medicine composition comprise, by weight, 10-15 parts of the root of red-rooted salvia, 10-60 parts of astragalus membranaceus, 10-30 parts of herba epimedii, 5-30 parts of sinensis and 3-30 parts of prepared rhubarb. Clinical researches show that 168 patients with chronic renal insufficiency are treated by the traditional Chinese medicine composition, a remarkable clinical effect is obtained, clinical symptoms are reduced, the clinical symptoms of some patients are basically eliminated, the renal functions of the patients can be remarkably improved, blood urea nitrogen (BUN) and creatinine (Scr) are obviously reduced, and total effective rate achieves 88.66%. Animal researches show that the traditional Chinese medicine composition can delay development of chronic renal failure, and the mechanism of the traditional Chinese medicine composition is relative to effects of effectively restraining precipitation of renal tissue collagen and secretion of TGF (transforming growth factor)-beta, accordingly restraining renal fibrosis, and the like. The traditional Chinese medicine composition is low in clinical application cost and excellent in curative effect, and is safe and reliable.

The invention relates to a short peptide having a kidney protection function as well as a preparation method and application thereof. The short peptide having the kidney protection function is characterized in that the amino acid sequence of the short peptide is QEQLERALNSS. The preparation method is characterized by comprising the following steps: successively coupling Ser, Asn, Leu, Ala, Arg, Glu, Leu, Gln, Glu and Gln on serine which is based on resin as a vector; after cracking, and settling with ice ether so as to obtain coarse peptide; and purifying with a high performance liquid chromatography (HPLC) so as to obtain the product. The invention also discloses application of the short peptide having the kidney protection function in the aspects of preparing formulations for treating renal ischemia-reperfusion injury along with acute tubular necrosis, local renal tissue inflammation and renal tubular epithelium cell apoptosis which are caused by the renal ischemia-reperfusion injury. The invention provides a novel clinic medicament for preventing and treating the renal ischemia-reperfusion injury, thereby bringing good news for patients suffering renal transplant.

In order to provide a method for detecting an unfavorable prognostic risk of renal cell carcinoma easily with quite high sensitivity and specificity, a methylome analysis was performed on normal renal tissues, and non-cancerous tissues and renal cell carcinomas derived from patients with renal cell carcinomas. The result revealed that it was possible to detect an unfavorable prognostic risk of renal cell carcinoma by detecting a DNA methylation level at at least one CpG site of FAM150A, GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A, TRH, FAM78A, ZNF671, SLC13A5, and NKX6-2 genes.

Renal injury and inflammation is diagnosed by detecting an elevation in GSK3b level or activity. Inflammation of bodily tissues such as renal tissue is inhibited by administration of GSK3b inhibitory compositions.

A protein [kidney regeneration factor (KRGF-1)] whose expression is increased at the time of regeneration of damaged tissues in patients with renal diseases is isolated, and a DNA encoding the protein and an antibody recognizing the protein are produced. These materials can be utilized in screening of therapeutic agents for regenerating damaged renal tissues and in diagnosis of renal damage.

The invention relates to applications of niclosamide ethanolamine salt and a medicinal composition of the niclosamide ethanolamine salt. After the niclosamide ethanolamine salt and the medicinal composition of the niclosamide ethanolamine salt are applied, an uncoupling effect can be achieved on the kidney tissue mitochondria, the excretion of proteinuria of mice with kidney diseases can be reduced, the glomerular sclerosis and renal tubular injuries can be improved, the level of serum creatinine can be reduced, and therefore, the niclosamide ethanolamine salt and medicinal composition of theniclosamide ethanolamine salt have a certain protection effect for the kidney diseases, and can be used for preventing and treating the kidney diseases.

The invention discloses application of a benzenesulfonamide compound in preparation of a medicine for treating and / or preventing acute kidney injury. The structural formula of the benzenesulfonamide compound is shown in the specification. The acute kidney injury is cisplatin or kidney ischemia reperfusion induced acute kidney injury. Experiments show that through administration of the benzenesulfonamide compound, the levels of BUN and SCr in serum of a mouse with acute kidney injury can be remarkably reduced, and the renal tissue form injury of the mouse with acute kidney injury can be remarkably relieved. The benzenesulfonamide compound has very important value for clinical prevention and treatment of acute kidney injury.

Methods for treating a patient having a disease or damage to at least one kidney are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. When administered, the cells promote and support the repair and regeneration of the diseased or damaged kidney tissue in the patient. Pharmaceutical compositions for use in the inventive methods, as well as kits for practicing the methods are also provided.

An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease.

Disclosed are cis-acting regulatory elements from a KIM-1 gene. The elements can be used to direct the expression of operably linked sequences in renal tissue.

The present invention relates to a method for preventing and / or treating a drug-induced renal tissue injury and its related conditions in a subject, comprising administering an effective amount of plasminogen to the subject. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and / or treating a drug-induced renal tissue injury and its related conditions in a subject.

The invention relates to a method for reproducing paraffin sections from kidney biopsy immunofluorescence frozen residual tissues, which comprises the following steps: quickly unfreezing the frozen residual kidney tissues by using a PBS buffer solution, dissolving OCT (Optical Coherence Tomography) gel, reproducing the paraffin sections, carrying out special dyeing by using the paraffin sections,and carrying out light microscope examination to obtain the paraffin sections toooooooo make up the condition that no glomerulus exists or the glomerulus is too little in the light microscope examination. The method has the advantages that the steps are simple, the operation is fast and convenient, the dyeing effect is good, the secondary kidney biopsy of the patient can be effectively avoided, and the pain and the economic burden of the patient are reduced.

The invention discloses a research method for the pharmacologic action of mangiferin on mouse diabetes. The research method comprises material selection and an experimental method, biochemical parameter evaluation, histological analysis, measurement of reactive oxygen species (ROS), determination of malondialdehyde (MDA) and antioxidase, analysis of renal tissue inflammatory factors, immunofluorescent staining, Western blotting and statistic analysis. According to the research method, a trichrome staining method is utilized to observe renal morphology; a kit is utilized to determine a blood biochemical index; levels of inflammatory cytokines, the antioxidase, the MDA and the ROS are determined; expression of fibronectin, collagen I and alpha-SMA is detected by an immunohistochemical method, and regulation of paths of TGF-beta 1 and phosphatase and tensin homolog / phosphatidylinositol 3-hydroxy kinase / protein kinase B (PTEN / PI3K / Akt) is detected by Western blotting; researches show thatthe mangiferin can significantly improve the renal dysfunction of diabetic mice; renal interstitial fibrosis can be prevented by reducing positive expression of fibronectin (FN), collagen type I (ColI) and alpha-smooth muscle actin (SMA) during therapy with the mangiferin; and meanwhile, mangiferin increases the antioxidase, reduces phosphorylation of the PI3K and Akt, inhibits the renal interstitial fibrosis, and provides more theoretical foundations for clinical application of traditional Chinese medicine in treating diabetes.

A shock wave lithotripter system and a method of performing shock wave calculus fragmentation using he same are provided. The system is composed of current commercial lithotripter (1) with protection device (7) made of special acoustic material. The protection device (7) could change the diffraction wave produced at the edge of the shock wave reflector, focusing lens, or shock wave generator, leading to the reduction of the energy of tensile wave in the focal region and the subsequent bubble cavitation effect in he renal tissue. Therefore, the propensity of shock wave induced tissue injure could be suppressed. Meanwhile, with the increase of the number of shock wave delivered, the effect of bubble cavitation effect be restored gradually to guarantee the success of stone fragmentation.

The invention relates to the application of cornuside in preparing pharmaceuticals used for curing diabetic nephropathy. The invention raises a novel application of cornuside in preparing pharmaceuticals used to cure diabetic nephropathy and provides a novel pharmaceutical choice for curing diabetic nephropathy. Through experimental verification, 0.1g-5.5g / kg dosage of cornuside has remarkable effects in curing diabetic nephropathy. Cornuside has satisfying effects of anti-inflammatory damage and improving renal function on renal tissue under the condition of diabetes, and is effective pharmaceutical in curing diabetic nephropathy.

The invention discloses an application of mPGES-2 as a drug target for preventing and / or treating kidney diseases. The invention proposes that the mPGES-2 is the cis-platinum-induced acute kidney injury drug target for the first time. Experiments show that mPGES-2 knockout can significantly reduce the levels of urea nitrogen and creatinine in the serum of a mouse with cis-platinum-induced acute kidney injury, significantly reduce the renal tissue form injury of the mouse with the cis-platinum-induced acute kidney injury and significantly improve the mitochondrial function in the kidneys of the mouse with acute kidney injury and reduce cell apoptosis. The results show that the cis-platinum-induced acute kidney injury can be reduced by mPGES-2 knockout, so that the mPGES-2 can be used as the target for preventing and / or treating the cis-platinum-induced acute kidney injury, and the mPGES-2 has very important significance on drug development and prevention and / or treatment of the diseases in the future.

The invention discloses application of NSC228155 in treating chronic renal interstitial fibrosis, and particularly relates to application of the NSC228155 in treating the chronic renal interstitial fibrosis by resisting inflammation and protecting renal tubular epithelial cells (RTECs). The NSC228155 can relieve pathological change of a chronic renal interstitial fibrosis mouse model, reduce the expression level of fibrosis factors of renal tissue of a mouse, reduce inflammatory reaction of renal tissue and fibroblasts, protect the RTECs in the fibrosis model and reverse the transdifferentiation effect of the RTECs.

The invention discloses a method for establishing a rat model with IgAN (immunoglobulin A nephropathy) glomerulosclerosis, which includes: firstly, performing intragastric administration of bovine serum albumin acidized liquor every other day for a rat fed for one week, and weekly performing penile intravenous injection of staphylococcus aureus enterotoxin B solution and intraperitoneal injection of complete Freund's adjuvant for the rat from the second week to the fourth week; and secondly, performing surgical nephrectomy twice on the fifth week and on the sixth week for the rat treated in the step 1, wherein five sixths of a kidney resected in the two operations. By the method, the time of making the rat model with IgAN glomerulosclerosis is shortened, and occurrence and development of renal tissue fibrosis are enhanced. Therefore, the model can better serve in medical research of IgA nephropathy.

The invention discloses application of eurycomanone in preparation of a medicine for preventing and treating acute kidney injury, and belongs to the field of biomedicines. According to the invention,animal in-vivo research finds that eurycoma longifolia extract and the eurycomanone can effectively relieve acute renal function decline and renal tissue injury of mice due to ischemia-reperfusion injury. The eurycomanone is a main active ingredient in eurycoma longifolia. In-vivo and in-vitro studies find that the eurycomanone protects the mitochondrial function by activating an AMPK / PGC-1[alpha]signal path, so that renal inflammatory response mediated by proximal renal tubular epithelial cell injury is relieved. Therefore, the eurycoma longifolia aqueous extract and the eurycomanone have anobvious kidney protection effect, do not have lethal toxic and side effects, and can be used for preparing acute kidney injury resisting medicines.

The invention discloses an application of an IgAN glomerular sclerosis rat model. The establishing method of the IgAN glomerular sclerosis rat model comprises the following steps of: step 1, selecting a rat, lavaging the rat with bovine serum albumin acidulated aqueous solution on the next day after the rat is raised for 1 week, injecting staphylococcus aureus B-type enterotoxin solution from the vein of the penis of the rat, and injecting complete a Freund's adjuvant from the enterocoelia of the rat during the period from the second week to the fourth week; and step 2, nephrectomizing the rat for two times at the fifth week and the sixth week, and cutting five sixths of the whole kidney at two times. The application of the rat model comprises the application in pathology research of an IgAN glomerular sclerosis process. According to the IgAN glomerular sclerosis rat model disclosed by the invention, the manufacturing time for the IgAN glomerular sclerosis rat model is shortened, the generation and the development of nephridial tissue fibrillation are enhanced, and the scientific research work of IgA nephropathy medical science can be better served.